Cisatracurium, also known by its popular trade name of Nimbex, is a bisbenzyltetrahydroisoquinolinium that is used as a medication for its neuromuscular-blocking and skeletal muscle relaxant properties. As such, it is produced by manufacturers and used adjunctively in anaesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
Cisatracurium was originally invented by the pharmaceutical products company Burroughs Wellcome Co. (GlaxoSmithKline) in 1989. Who subsequently entered it into clinical development between the years 1992 to 1994. It gained regulatory approval for sale on the medical marketplace in the United States by the FDA in 1995, where the company held the exclusive right to it under the brand name of Nimbex.
Currently, cisatracurium has entered into the generic drugs space making it both attractive and cost-effective for cisatracurium manufacturers and cisatracurium suppliers to list for sale. As such, it can commonly be found on the pharmaceutical products list of distributors across the global marketplace. Where it is available for wholesale order at a variety of cost and price points.
Method of action of cisatracurium:
Cisatracurium is a nondepolarizing skeletal muscle relaxant for intravenous administration. It belongs to a group of non-depolarizing neuromuscular-blocking drugs that target cholinergic receptors, blocking neuromuscular transmission. Cisatracurium binds to nicotinic acetylcholine receptors in the motor endplate, blocking access for other molecules. During this binding, the receptor is activated and triggers depolarization. As cisatracurium is not degraded in the neuromuscular junction, like traditional receptor activating substances, it stays engaged on the receptor. As such, the membrane remains depolarized and unresponsive to any other impulse, culminating in a constant state of muscle paralysis.
Form and dosage of cisatracurium:
The final form and packaging of cisatracurium are dependent on the manufacturers and suppliers, as well as the specific distributors and order. However, it predominantly is found in forms including, vials, solution of injections, ampules, and prefilled pens. For neuromuscular blockade during surgery, the adult recommended dose is an initial 150 micrograms/kg followed by a maintenance dose of 30 micrograms/kg every 20 minutes. However, these values are highly patient and situation-specific. For more information please refer to the manufacturers’ literature or contact an accredited healthcare provider.
Cisatracurium on Pipelinepharma:
Currently, at the time of writing, we have found 2 verified cisatracurium manufacturers and cisatracurium suppliers from our online global list of B2B sellers. These manufacturers, suppliers, and distributors are located in various locations including the European Union and India. Each company and their pharmaceutical products list displayed on our online B2B platform has been verified by the Pipelinepharma team. This ensures seller reputability and reduces sourcing mileage, allowing for a fluent business experience for all involved parties.
Price of cisatracurium and how to buy:
A cursory search online reveals an approximate cost for wholesale cisatracurium is $110.30 – $135.68 for 10 x 5 millilitres, coming to $2.21 – $2.71 for a per-unit price. As with all drugs, the specific cost for B2B purchase is highly dependent on circumstantial factors. As such, the values indicated are solely intended to serve as generalisations of current marketplace conditions.
Although the prices on the B2B wholesale Pipelinepharma marketplace remain confidential between both B2B parties, the seller may choose to list the desired price to facilitate the online transaction. If so, an ‘Accept’ and ‘Negotiate’ button will be displayed through the online interface, with a ‘Get offer’ button being shown in the absence. This makes it easy to find new qualified sellers for your pharmaceutical business. Simply use our online search tool, filter by your wanted criteria, and finally select the desired listing.